Komal Jhaveri, Breast Medical Oncologist, Section Head of the Endocrine Therapy Research Program shared by Memorial Sloan Kettering Cancer Center, on LinkedIn:
“This approval isn’t just data – it’s more time with family, more birthdays, more milestones, more hope for our patients living with ESR1-mutated breast cancer. Nice to see NCCN endorsement and FDA approval for it.”
Quoting Memorial Sloan Kettering Cancer Center:
“The U.S. Food and Drug Administration (FDA) has approved imlunestrant in combination with abemaciclib for patients with ER-positive, HER2-negative advanced breast cancer with an ESR1 gene mutation who were previously treated with hormone therapy.
The approval is based on results from the EMBER-3 clinical trial, led by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering Cancer Center (MSK). The combination resulted in a median progression-free survival of 11.1 months, compared with 5.5 months for imlunestrant alone.
‘This latest approval will change how many breast cancers are treated’
Dr. Jhaveri says.
Learn more about the FDA approval and what it could mean for patients”
You may also be interested in: FDA Updates Regulations to Expand Alternatives to Animal Testing in Drug Development
